A new epigenetic challenge: Systemic lupus erythematosus

Advances in Experimental Medicine and Biology

Volumn 711, Issue , 2011, Pages 117-136

  Javierre, Biola M ^a   Richardson, Bruce ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE C DELTA; RNA 18S; RNA 28S; HISTONE;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; REVIEW;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 79958260145     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-8216-2_9     Document Type: Article

References (132)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus Lancet, 2007; 369(9561):587-596. (Pubitemid 46241445)
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358(9):929-939. (Pubitemid 351397092)
3. Cooper GS, Dooley MA, Treadwell EL et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 2002; 46(7):1830-1839. (Pubitemid 34774515)
4. Johnson AE, Gordon C, Palmer RG et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England.Relationship to ethnicity and country of birth. Arthritis Rheum; 1995; 38(4):551-558.
5. Urowitz MB, Bookman AA, Koehler BE et al. The bimodal mortality pattern ofsystemic lupus erythematosus. Am J Med 1976; 60(2):221-225.
6. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006; 24(5):348-362. (Pubitemid 44332871)
7. Munoz LE, Gaipl US, Franz S, et al. SLE-a disease of clearance deficiency? Rheumatology (Oxford) 2005; 44(9):1101-1107.
8. Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers ofpatients with systemic lupus erythematosus. Arthritis Rheum 2002; 46(1):191-201. (Pubitemid 34121664)
9. Isenberg DA, Manson JJ, Ehrenstein MR, et al. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007; 46(7):1052-1056. (Pubitemid 47050602)
10. Ng KP, Manson JJ, Rahman A et al. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55(6):900-904. (Pubitemid 44917463)
11. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991; 12(5):154-159.
12. Fujii Y, Fujii K, Tanaka Y. Attempt to correct abnormal signal transduction in T-lymphocytes from systemic lupus erythematosus patients. Autoimmun Rev 2006; 5(2):143-144. (Pubitemid 43129547)
13. Graham RR, Kozyrev SV, Baechler EC et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38(5):550-555.
14. Houssiau FA, Lefebvre C, Vanden Berghe M et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4(5):393-395.
15. Sullivan KE. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000; 26(2):229-256, v-vi. (Pubitemid 30198758)
16. Rhodes B, Vyse TJ. The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology (Oxford) 2008; 47(11):1603-1611.
17. Moser KL, Kelly JA, Lessard CJ et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10(5):373-379.
18. Jacobson DL, Gange SJ, Rose NR et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84(3):223-243. (Pubitemid 27398022)
19. Sanchez-Guerrero J, Karlson EW, Liang MH et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40(5):804-808. (Pubitemid 27199994)
20. Mok CC, Lau CS, Ho CT et al. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 1999; 28(6):357-362. (Pubitemid 30033049)
21. Lahita RG, Bradlow HL, Ginzler E,et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30(3):241-248. (Pubitemid 17098574)
22. Lahita RG, Bradlow L, Fishman J et al. Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arthritis Rheum 1982; 25(7):843-846. (Pubitemid 12022161)
23. Folomeev M, Dougados M, Beaune J et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992; 1(3):191-195.
24. Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 1992; 19(9):1333-1336.
25. Roubinian JR, Talal N, Greenspan JS et al. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978; 147(6):1568-1583. (Pubitemid 8372952)
26. Roubinian JR, Papoian R, Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 1977; 59(6):1066-1070. (Pubitemid 8131060)
27. Elbourne KB, Keisler D, McMurray RW. Differential effects ofestrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus 1998; 7(6):420-427. (Pubitemid 28410189)
28. Kremer Hovinga IC, Koopmans M, de Heer E et al. Chimerism in systemic lupus erythematosus-three hypotheses. Rheumatology (Oxford) 2007; 46(2):200-208. (Pubitemid 46189776)
29. James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18(5):462-467. (Pubitemid 44200328)
30. Gross AJ, Hochberg D, Rand WM et al. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005; 174(11):6599-6607. (Pubitemid 40705620)
31. Sundar K, Jacques S, Gottlieb P et al. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production ofanti-dsDNA and anti-Sm antibodies. J Autoimmun 2004; 23(2):127-140. (Pubitemid 39485794)
32. Poole BD, Scofield RH, Harley JB et al. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006; 39(1):63-70. (Pubitemid 43878521)
33. Kaufman KM, Kirby MY, Harley JB et al. Peptide mimics of a major lupus epitope of SmB/B'. Ann N Y Acad Sci 2003; 987:215-229. (Pubitemid 36584025)
34. Balada E, Ordi-Ros J, Vilardell-Tarres M. Molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity. Rev Med Virol 2009; 19(5):273-286.
35. Chu JL, Drappa J, Parnassa A et al. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 1993; 178(2):723-730. (Pubitemid 23218222)
36. Cooper GS, Parks CG, Treadwell EL et al. Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol 2004; 31(10):1928-1933. (Pubitemid 39336715)
37. Portela A, Esteller M. Epigenetic modifications and their relevance to disease Nat Biotech., 2010.
38. Strickland FM, Richardson BC. Epigenetics in human autoimmunity. Epigenetics in autoimmunity-DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 2008; 41(4):278-286.
39. Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 1999; 107 Suppl 5:737-742. (Pubitemid 29527778)
40. Jarvinen P, Aho K. Twin studies in rheumatic diseases. Semin Arthritis Rheum 1994; 24(1):19-28.
41. Singal R, Ginder GD. DNA methylation. Blood 1999; 93(12):4059-4070. (Pubitemid 29279247)
42. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462(7271):315-322.
43. Bird A. Molecular biology. Methylation talk between histones and DNA. Science 2001; 294(5549):2113-2115. (Pubitemid 33150658)
44. Cedar H. DNA methylation and gene activity. Cell 1988; 53(1):3-4.
45. Ehrlich M, Gama-Sosa MA, Huang LH et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982; 10(8):2709-2721.
46. Tuck-Muller CM, Narayan A, Tsien F et al. DNAhypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet Cell Genet 2000; 89(1-2):121-128. (Pubitemid 30435274)
47. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31(2):89-97. (Pubitemid 43221841)
48. Rai K, Huggins IJ, James SR et al. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase and gadd45. Cell 2008; 135(7):1201-1212.
49. Richardson B. Effect ofan inhibitor ofDNA methylation on T-cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol 1986; 17(4):456-4570.
50. Yung R, Powers D, Johnson K et al. Mechanisms of drug-induced lupus. II. T-cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97(12):2866-2871. (Pubitemid 26197100)
51. Richardson BC, Strahler JR, Pivirotto TS et al. Phenotypic and functional similarities between 5-azacytidine-treated T-cells and a T-cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 1992; 35(6):647-662.
52. Cornacchia E, Golbus J, Maybaum J et al. Hydralazine and procainamide inhibit T-cell DNA methylation and induce autoreactivity. J Immunol 1988; 140(7):2197-2200. (Pubitemid 18098475)
53. Quddus J, Johnson KJ, Gavalchin J et al. Treating activated CD4+ T-cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 1993; 92(1):38-53. (Pubitemid 23208979)
54. Yung R, Chang S, Hemati N et al. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997; 40(8):1436-1443. (Pubitemid 27430954)
55. Salvador JM, Hollander MC, Nguyen AT et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 2002; 16(4):499-508. (Pubitemid 34442575)
56. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152(7):3685-3692. (Pubitemid 24098067)
57. Kaplan MJ, Lewis EE, Shelden EA et al. The apoptotic ligands TRAIL, TWEAK and Fas ligand mediate monocyte death induced by autologous lupus T-cells. J Immunol 2002 169(10):6020-6029. (Pubitemid 35291710)
58. Yu D, Zhu FG, Bhagat L et al. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 2002; 297(1):83-90.
59. Messina JP, GilkesonGS, Pisetsky DS. The influence ofDNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol 1993; 147(1):148-157. (Pubitemid 23100973)
60. Wen ZK, Xu W, Xu L et al. DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-nonsusceptible mice. Rheumatology (Oxford) 2007; 46(12):1796-1803. (Pubitemid 350168294)
61. Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol 1995; 15(6):284-292.
62. Yung RL, Quddus J, Chrisp CE et al. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995; 154(6):3025-3035.
63. Golbus J, Palella TD, Richardson BC. Quantitative changes in T-cell DNA methylation occur during differentiation and ageing. Eur J Immunol 1990; 20(8):1869-1872. (Pubitemid 20290926)
64. Zhang Z, Deng C, Lu Q et al. Age-dependent DNA methylation changes in the ITGAL (CD11a) promoter. Mech Ageing Dev 2002; 123(9):1257-1268. (Pubitemid 34518557)
65. Richardson B, Scheinbart L, Strahler J et al. Evidence for impaired T-cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990; 33(11):1665-1673.
66. Luo Y, Li Y, Su Y et al. Abnormal DNA methylation in T-cells from patients with subacute cutaneous lupus erythematosus. Br J Dermatol 2008; 159(4):827-833.
67. Javierre BM, Fernandez AF, Richter J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 2010; 20(2):170-179.
68. Lei W, Luo Y, Lei W et al. Abnormal DNA methylation in CD4+ T-cells from patients with systemic lupus erythematosus, systemic sclerosis and dermatomyositis. Scand J Rheumatol 2009;1-6.
69. Okada M, Ogasawara H, Kaneko H et al. Role of DNA methylation in transcription of human endogenous retrovirus in the pathogenesis of systemic lupus erythematosus. J Rheumatol 2002; 29(8):1678-1682. (Pubitemid 34831242)
70. Knight SJ, Flannery AV, Hirst MC et al. Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 1993; 74(1):127-134. (Pubitemid 23219884)
71. Sekigawa I, Okada M, Ogasawara H et al. Lessons from similarities between SLE and HIV infection. J Infect 2002; 44(2):67-72. (Pubitemid 34785343)
72. Sekigawa I, Ogasawara H, Kaneko H et al. Retroviruses and autoimmunity. Intern Med 2001; 40(2):80-86. (Pubitemid 33665232)
73. Naito T, Ogasawara H, Kaneko H et al. Immune abnormalities induced by human endogenous retroviral peptides: with reference to the pathogenesis of systemic lupus erythematosus. J Clin Immunol 2003; 23(5):371-376. (Pubitemid 37083191)
74. Deng C, Kaplan MJ, Yang J et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T-lymphocytes from lupus patients. Arthritis Rheum 2001; 44(2):397-407.
75. Ogasawara H, Okada M, Kaneko H et al. Possible role of DNA hypomethylation in the induction of SLE: relationship to the transcription of human endogenous retroviruses. Clin Exp Rheumatol 2003; 21(6):733-738. (Pubitemid 38008756)
76. Kammer GM, Perl A, Richardson BC et al. Abnormal T-cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 2002; 46(5):1139-1154. (Pubitemid 34525819)
77. Miyamoto A, Nakayama K, Imaki H et al. Increased proliferation of B-cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 2002; 416(6883):865-869. (Pubitemid 34453744)
78. Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann N YAcad Sci 2007; 1108:127-136. (Pubitemid 47528726)
79. Wu J, Zhou T, He J et al. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 1993; 178(2):461-468. (Pubitemid 23218194)
80. Mizugaki M, Yamaguchi T, Ishiwata S et al. Alteration of DNA methylation levels in MRL lupus mice. Clin Exp Immunol 1997; 110(2):265-269. (Pubitemid 27469600)
81. Sawalha AH, Jeffries M. Defective DNA methylation and CD70 overexpression in CD4+ T-cells in MRL/ lpr lupus-prone mice. Eur J Immunol 2007; 37(5):1407-1413. (Pubitemid 46925323)
82. Yoshida H, Yoshida M, Merino R et al. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice. Eur J Immunol 1990; 20(9):1989-1993. (Pubitemid 20355621)
83. Schauenstein K, Csordas A, Kromer G et al. In-vivo treatment with 5-azacytidine causes degeneration ofcentral lymphatic organs and induces autoimmune disease in the chicken. Int J Exp Pathol 1991; 72(3):311-318.
84. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41(1):87-95.
85. Huang S, Rothblum LI, Chen D. Ribosomal chromatin organization. Biochem Cell Biol 2006; 84(4):444-449. (Pubitemid 44703649)
86. Lu Q, Kaplan M, Ray D et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 2002; 46(5):1282-1291. (Pubitemid 34525836)
87. Hogg N, Laschinger M, Giles K et al. T-cell integrins: more than just sticking points. J Cell Sci 2003; 116(Pt 23):4695-4705. (Pubitemid 37541213)
88. Richardson B, Powers D, Hooper F et al. Lymphocyte function-associated antigen 1 overexpression and T-cell autoreactivity. Arthritis Rheum 1994; 37(9):1363-1372. (Pubitemid 24320756)
89. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005; 105(12):4845-4848. (Pubitemid 40807312)
90. Puig-Kroger A, Sanchez-Elsner T, Ruiz N et al. RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. Blood 2003; 102(9):3252-3261. (Pubitemid 37314764)
91. Kaplan MJ, Lu Q, Wu A et al. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T-cells. J Immunol 2004; 172(6):3652-3661. (Pubitemid 38337948)
92. van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol 2000; 85(6):681-685.
93. Kobata T, Jacquot S, Kozlowski S et al. CD27-CD70 interactions regulate B-cell activation by T-cells. Proc Natl Acad Sci USA 1995; 92(24):11249-11253.
94. Luo Y, Zhang X, Zhao M et al. DNA demethylation of the perforin promoter in CD4(+) T-cells from patients with subacute cutaneous lupus erythematosus. J Dermatol Sci 2009; 56(1):33-36.
95. Oelke K, Lu Q, Richardson D et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T-cells and T-cells treated with DNA methylation inhibitors. Arthritis Rheum 2004; 50(6):1850-1860. (Pubitemid 38725098)
96. Luo Y, Zhao M, Lu Q. Demethylation of promoter regulatory elements contributes to CD70 overexpression in CD4+ T-cells from patients with subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2009.
97. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T-cells and T-cells treated with lupus-inducing drugs. J Immunol 2005; 174(10):6212-6219. (Pubitemid 40663812)
98. Lu Q, Wu A, Tesmer L et al. Demethylation of CD40LG on the inactive X in T-cells from women with lupus. J Immunol 2007; 179(9):6352-6358.
99. Zhou Y, Yuan J, Pan Y et al. T-cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol 2009; 132(3):362-370.
100. Mi XB, Zeng FQ. Hypomethylation of interleukin-4 and -6 promoters in T-cells from systemic lupus erythematosus patients. Acta Pharmacol Sin 2008; 29(1):105-112.
101. Evans JL, Boyle WJ, Ting JP. Molecular basis of elevated c-myb expression in the abnormal L3T4-, Lyt-2- T-lymphocytes of autoimmune mice. J Immunol 1987; 139(10):3497-3505. (Pubitemid 18022007)
102. Eleftheriades EG, Boumpas DT, Balow JE et al. Transcriptional and posttranscriptional mechanisms are responsible for the increased expression of c-myc protooncogene in lymphocytes from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1989; 52(3):507-515. (Pubitemid 19214184)
103. Strahl BD, Allis CD. The language ofcovalent histone modifications. Nature 2000; 403(6765):41-45.
104. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14(14):R546-R551.
105. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005; 41(16):2381-2402. (Pubitemid 41540617)
106. Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res 2008; 102(8):873-887. (Pubitemid 351591544)
107. Boix-Chornet M, Fraga MF, Villar-Garea A et al. Release of hypoacetylated and trimethylated histone H4 is an epigenetic marker of early apoptosis. J Biol Chem 2006; 281(19):13540-13547. (Pubitemid 43855267)
108. Dieker JW, Fransen JH, van Bavel CC et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 2007; 56(6):1921-1933. (Pubitemid 47110391)
109. van Bavel CC, Dieker J, Muller S et al. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol Immunol 2009; 47(2-3):511-516.
110. Mishra N, Reilly CM, Brown DR et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111(4):539-552. (Pubitemid 36228011)
111. Reilly CM, Mishra N, Miller JM et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004 173(6):4171-4178. (Pubitemid 39280783)
112. Forster N, Gallinat S, Jablonska J et al. p300 protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice. J Immunol 2007; 178(11):6941-6948. (Pubitemid 46847420)
113. Garcia BA, Busby SA, Shabanowitz J et al. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 2005 ; 4(6):2032-2042. (Pubitemid 41814269)
114. Hu N, Qiu X, Luo Y et al. Abnormal histone modification patterns in lupus CD4+ T-cells. J Rheumatol 2008; 35(5):804-810. (Pubitemid 351747120)
115. Mishra N, Brown DR, Olorenshaw IM et al. Trichostatin A reverses skewed expression of CD154, interleukin-10 and interferon-gamma gene and protein expression in lupus T-cells. Proc Natl Acad Sci USA 2001; 98(5):2628-2633. (Pubitemid 32209533)
116. Zhang Z, Song L, Maurer K et al. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun, 2009.
117. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5(1):37-50.
118. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007; 150(7):829-831. (Pubitemid 46536629)
119. Brogdon JL, Xu Y, Szabo SJ et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109(3):1123-1130. (Pubitemid 46220659)
120. Javierre BM, Esteller M, Ballestar E. Epigenetic connections between autoimmune disorders and haematological malignancies. Trends Immunol 2008; 29(12):616-623.
121. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32(3-4):189-194.
122. Wang Y, Liang Y, Lu Q. MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clin Genet 2008; 74(4):307-315.
123. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116(2):281-297.
124. Lujambio A, Calin GA, Villanueva A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA, 2008. 105(36):13556-13561.
125. Dai Y, Huang YS, Tang M et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007; 16(12):939-946.
126. Tang Y, Luo X, Cui H et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60(4):1065-1075.
127. Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16(5):534-540. (Pubitemid 39128320)
128. Mannik M, Merrill CE, Stamps LD et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30(7):1495-1504. (Pubitemid 36835445)
129. Amoura Z, Koutouzov S, Chabre H et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43(1):76-84. (Pubitemid 30368215)
130. Kowal C, Degiorgio LA, Lee JY et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006; 103(52):19854-19859. (Pubitemid 46037520)
131. Becker-Merok A, Kalaaji M, Haugbro K et al. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res Ther 2006; 8(6):R162.
132. Siegert CE, Daha MR, Swaak AJ et al. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1993; 67(3 Pt 1):204-209. (Pubitemid 23186401)